ArticleEuropean radiology2017
Dual energy CT allows for improved characterization of response to antiangiogenic treatment in patients with metastatic renal cell cancer.
Article in European radiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 54 citations in OpenAlex.
- Spectral CT in renal cell carcinoma: the promising role of dual-energy and photon-counting techniques.Abdominal radiology (New York) · 2026Review
- Dual-energy CT iodine concentration as a biomarker for immunotherapy treatment response in metastatic melanoma and renal cell carcinoma patients.European radiology · 2025Article
- Beyond Conventional CT: Role of Dual-Energy CT in Monitoring Response to Therapy in Abdominal Malignancies.Radiology. Imaging cancer · 2025Review
- Current trends in the characterization and monitoring of vascular response to cancer therapy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- Intra-patient variability of iodine quantification across different dual-energy CT platforms: assessment of normalization techniques.European radiology · 2024Article
- Dual-Energy CT in Oncologic Imaging.Tomography (Ann Arbor, Mich.) · 2024Review
- Added value of arterial enhancement fraction derived from dual-energy computed tomography for preoperative diagnosis of cervical lymph node metastasis in papillary thyroid cancer: initial results.European radiology · 2024Article
- Dual-Layer Spectral Detector Computed Tomography Quantitative Parameters: A Potential Tool for Lymph Node Activity Determination in Lymphoma Patients.Diagnostics (Basel, Switzerland) · 2024Article
- Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Extracellular Volume Fraction Derived From Dual-Layer Spectral Detector Computed Tomography for Diagnosing Cervical Lymph Nodes Metastasis in Patients With Papillary Thyroid Cancer: A Preliminary Study.Frontiers in oncology · 2022Article
- Quantitative contrast enhanced dual energy CT to predict avascular necrosis: a feasibility study of proximal humerus fractures.BMC medical imaging · 2021Article
- Inter-scan and inter-scanner variation of quantitative dual-energy CT: evaluation with three different scanner types.European radiology · 2021Article
- Use of dual-energy CT for renal mass assessment.European radiology · 2021Review
- Intra-individual consistency of spectral detector CT-enabled iodine quantification of the vascular and renal blood pool.European radiology · 2019Article
- The application of dual-energy computed tomography in the diagnosis of musculoskeletal disorders: a review of current concepts and applications.La Radiologia medica · 2019Review
- Early Changes in CT Perfusion Parameters: Primary Renal Carcinoma Versus Metastases After Treatment with Targeted Therapy.Cancers · 2019Article
- How accurate and precise are CT based measurements of iodine concentration? A comparison of the minimum detectable concentration difference among single source and dual source dual energy CT in a phantom study.European radiology · 2019Article
- Therapy Effects of Advanced Hypopharyngeal and Laryngeal Squamous Cell Carcinoma: Evaluated using Dual-Energy CT Quantitative Parameters.Scientific reports · 2018Article
- Dual energy CT iodine map for delineating inflammation of inflammatory arthritis.European radiology · 2017Observational
- Imaging and Screening of Kidney Cancer.Radiologic clinics of North America · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the potential role of dual energy CT (DECT) to visualize antiangiogenic treatment effects in patients with metastatic renal cell cancer (mRCC) while treated with tyrosine-kinase inhibitors (TKI).
methods26 patients with mRCC underwent baseline and follow-up single-phase abdominal contrast enhanced DECT scans. Scans were performed immediately before and 10 weeks after start of treatment with TKI. Virtual non-enhanced (VNE) and colour coded iodine images were generated. 44 metastases were measured at the two time points. Hounsfield unit (HU) values for VNE and iodine density (ID) as well as iodine content (IC) in mg/ml of tissue were derived. These values were compared to the venous phase DECT density (CTD) of the lesions. Values before and after treatment were compared using a paired Student's t test.
resultsBetween baseline and follow up, mean CTD and DECT-derived ID both showed a significant reduction (p < 0.005). The relative reduction measured in percent was significantly greater for ID than for CTD (49.8 ± 36,3 % vs. 29.5 ± 20.8 %, p < 0.005). IC was also significantly reduced under antiangiogenic treatment (p < 0.0001).
conclusionsDual energy CT-based quantification of iodine content of mRCC metastases allows for significantly more sensitive and reproducible detection of antiangiogenic treatment effects. KEY POINTS: • A sign of tumour response to antiangiogenic treatment is reduced tumour perfusion. • DECT allows visualizing iodine uptake, which serves as a marker for vascularization. • More sensitive detection of antiangiogenic treatment effects in mRCC is possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.